Experience

Atea Pharmaceuticals, Inc

• United States
• Biotechnology Research
• 1 - 100 Employee

• Executive Vice President, Preclinical Development

  • Feb 2022 - Present

  Responsible for development and execution of the overall global preclinical strategy for Atea, including Virology, Drug Metabolism and Pharmacokinetics, and Toxicology. Strategic company focus is on discovering, developing, and commercializing therapies to address unmet medical needs of patients with life-threatening viral diseases. Responsible for development and execution of the overall global preclinical strategy for Atea, including Virology, Drug Metabolism and Pharmacokinetics, and Toxicology. Strategic company focus is on discovering, developing, and commercializing therapies to address unmet medical needs of patients with life-threatening viral diseases.



Merck

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Vice President, Pharmacokinetics, Pharmacodynamics, & Drug Metabolism (PPDM)

  • Jul 2018 - Dec 2021

  Responsible for leadership of the PPDM group (consisting of ~400 Ph.D. and associate level staff members across West Point, Kenilworth, Rahway, Palo Alto, Upper Gwynedd, Boston, and South San Francisco). Scope includes ADME, Bioanalytics, Quantitative Pharmacology and Pharmacometrics, and Operations for all small and large molecule drug discovery and development programs across Merck.

• Associate Vice President, Formulation Sciences

  • Jul 2017 - Jun 2018

  Responsible for leadership of the Formulation Sciences group (consisting of up to 70 Ph.D. and associate level staff members across West Point and Rahway). Responsibilities include developing oral formulations (both fit-for-purpose and final market formulations) for clinical trials, including establishing the composition and process to manufacture oral formulations, characterizing the physicochemical properties of the drug candidates and finished products, supporting manufacturing of clinical supplies from first-in-human testing through Phase IIB trials, and partnering with Merck Manufacturing Division to transition programs into late stage development and commercialization Show less

• Associate Vice President, Biopharmaceutics and Specialty Dosage Forms (PSCS)

  • Oct 2015 - Jun 2017

  Responsible for leadership of the Biopharmaceutics and Specialty Dosage Forms group within the Department of Pharmaceutical Sciences and Clinical Supply (consisting of Ph.D. and associate level staff members across West Point, Rahway, Kenilworth, Hoddesdon, UK, and Oss, NL). Responsibilities of the group include biopharmaceutics assessment/support of all PSCS development activities (including preclinical study execution and modeling and simulation); development of new inhaled therapeutics and the support of in-line/marketed respiratory products; preparation (on and off-site) of fit for purpose dosage forms to facilitate the execution of first in human and other exploratory clinical studies through Phase IB; development, scale up and validation of specialty dosage forms; non-GMP small molecule and non-GMP/GMP respiratory pilot plant operations in NJ. Show less

• Associate Vice President, Preclinical ADME (PPDM)

  • Jun 2012 - Oct 2015

  Responsible for providing strategic, scientific, and operational leadership for the Preclinical ADME group across West Point, Rahway, Kenilworth, and Boston. Responsibilities include supporting preclinical discovery and development for small molecules, driving line of sight from discovery through development, and providing high-quality regulatory submissions.

• Sr. Director and Scientific Lead; Pharmacokinetics, Pharmacodynamics & Drug Metabolism (PPDM)

  • May 2009 - May 2012

• Senior Director, Clinical PK/PD and DMPK Functional Area Operations Lead

  • Jan 2008 - Apr 2009

• Director, Clinical PK/PD

  • Jun 2006 - Dec 2007

• Associate Director, Pharmacokinetics & Biopharmaceutics

  • Oct 2003 - May 2006

• Research Fellow

  • Feb 2001 - Sep 2003

• Senior Research Pharmacokineticist

  • Nov 1996 - Jan 2001